title: Effects of febuxostat on platelet-derived microparticles and adiponectin in patients with hyperuricemia.
abstract: Platelet-derived microparticles (PDMPs) and adiponectin play an important role in the development of atherothrombosis. We investigated the effect of febuxostat on circulating PDMP levels and adiponectin in hyperuricemic patients. Levels of PDMP and biomarkers were measured using an ELISA at baseline and after 2 and 6 months of treatment. Plasma levels of PDMPs and biomarkers were higher, while those of adiponectin were lower in hyperuricemic patients than in normouricemic controls. Uric acid and interleukin (IL)-6 levels decreased significantly in hyperuricemic patients after 2 months of febuxostat treatment. However, PDMP and biomarkers decreased significantly in hyperuricemic patients after only 6 months of febuxostat treatment and adiponectin increased significantly. These results suggest that the effects of febuxostat for PDMPs seen may be the effect on xanthine oxidase but not the decrease of uric acid, and febuxostat may be beneficial for primary prevention of atherothrombosis in hyperuricemic patients.
authors.affiliation: aFirst Department of Internal Medicine, Kansai Medical University, Osaka bDivision of Internal Medicine, Daiwa Hospital, Japan.
authors.forename: Tohru
authors.initials: T
authors.lastname: Nishizawa
authors.forename: Takehito
authors.initials: T
authors.lastname: Taniura
authors.forename: Shosaku
authors.initials: S
authors.lastname: Nomura
mesh_terms: D052242:Adiponectin / Q000819:agonists* / Q000097:blood; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015415:Biomarkers / Q000097:blood; D001792:Blood Platelets / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D002341:Carotid Artery Thrombosis / Q000097:blood / Q000209:etiology / Q000473:pathology / Q000517:prevention & control*; D016022:Case-Control Studies; D055252:Cell-Derived Microparticles / Q000737:chemistry / Q000187:drug effects* / Q000473:pathology; D000069465:Febuxostat / Q000627:therapeutic use*; D005260:Female; D006074:Gout Suppressants / Q000627:therapeutic use*; D006801:Humans; D033461:Hyperuricemia / Q000097:blood / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D015850:Interleukin-6 / Q000097:blood; D008297:Male; D008875:Middle Aged; D014527:Uric Acid / Q000037:antagonists & inhibitors / Q000097:blood; D014969:Xanthine Oxidase / Q000037:antagonists & inhibitors / Q000097:blood
chemical_list: C499918:ADIPOQ protein, human; D052242:Adiponectin; D015415:Biomarkers; D006074:Gout Suppressants; C508600:IL6 protein, human; D015850:Interleukin-6; D000069465:Febuxostat; D014527:Uric Acid; D014969:Xanthine Oxidase